Fair value · Sarepta Therapeutics, Inc. (SRPT) · updated 2026-11-19 · from 10-K FY2025
Sarepta Therapeutics trades at $14.66. That price implies a 9.8% free-cash-flow yield.
Cboe · delayed 15 min · as of 20:05 ET
Are those assumptions reasonable? Use SRPT’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.
What the price implies
- FCF yield
- 9.8%
free cash flow ÷ enterprise value (10.2× EV/FCF)
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 20:05 ET.
Inputs come from the FY2025 10-K filed (accession 0001193125-26-084144); set your own on the sliders below. Research, not investment advice.
The filing behind these numbers
Sarepta Therapeutics, Inc.- Revenue
- $2.2B
- Diluted EPS
- $-7.13
- Free cash flow
- $-307.5M
- operating cash flow − capital expenditure
- Diluted shares
- 100.1M
- weighted average
10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-02 · accession 0001193125-26-084144
Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q3 FY2026 (filed 2026-11-05).
Open this filing on sec.govNeed SRPT data in your own agent or pipeline?
The valuation data behind this page — DCF fair value, margin of safety, PE vs industry, analyst estimates — is also available programmatically through the EvidInvest MCP server & financial data API for Claude, Cursor, or any MCP client and HTTP pipeline.